How long is the study?
The study could last up to approximately 68 weeks in total (around 15 months).
Complete this brief questionnaire
Check eligibilityIf you are interested in learning more about this study, we encourage you to complete a brief questionnaire to help determine if you are eligible to participate and be referred to a site recruiting in your area for further evaluation.
Am I eligible?What is the purpose of the study?
To evaluate how effective and safe Dupilumab is at relieving symptoms of UC and reducing inflammation in the colon in adult patients.
What is the investigational medication?
The study could last up to approximately 68 weeks in total (around 15 months).
Each participant will have between 6-7 clinic visits during the study.
Additional visits may be required if the study doctor considers them necessary for your safety.
This study will include about 100 participants at about 90 clinics around the world.
This is the medication being studied to see if patient symptoms improve while taking it.
The medication is not yet approved for general use by regulatory authorities.
A placebo is an inactive substance or treatment that looks the same and is given in the same way as the investigational medication that is being studied.
An eosinophilic phenotype means that your UC may be caused by a specific group of proteins, leading to inflammation in your colon.
All study-related medical care related to the study is provided, including study-related exams, study-related medications and other study-related medical care. There is no insurance required to participate. All study-related medical care will be explained.
Yes, after you complete the online questionnaire and give permission to be contacted, a study representative will contact with you. You can ask questions at any time, before deciding to participate and during study conduct.
Complete this brief questionnaire (approximately 5 minutes) to determine if you are eligible to participate in this clinical study and be referred to a site recruiting in/near your area.
V1.0, 24Oct2023